In February, Amgen published a study in Nature Metabolism about AMG 133, a novel molecule with potential for treating obesity.

Regor Therapeutics Group has announced the launch of its Phase 2 trial on RGT-075, an oral, highly selective GLP-1 receptor agonist.

Triamcinolone, a synthetic corticosteroid, acts as a potent glucocorticoid receptor agonist, mainly used to treat autoimmune diseases such as psoriasis, lupus, and rheumatoid arthritis.

Amylyx Pharmaceuticals released initial results from their Phase 3 PHOENIX study, a 48-week global, randomized, double-blind, placebo-controlled trial, assessing AMX0035 in ALS patients.

Tharimmune revealed on their website plans to start a Phase 1 trial for TH104, assessing safety and bioavailability, with early results due Q2 2024.

VISEN Reveals China's Endorsement of Submission for the Biologic Drug License Concerning Lonapegsomatropin.

Nifedipine is a small molecule drug that acts as a blocker of voltage-dependent calcium channels (VDCCs), which are involved in the regulation of calcium ions in the cardiovascular system.

Akari Therapeutics and Peak Bio have reached a final merger agreement, positioning themselves as partners to develop a broader portfolio with an innovative Antibody Drug Conjugate (ADC) technology base.

In February, University of Leicester and Leicester Diabetes Centre experts published a summary of obesity treatments in "International Journal of Obesity," highlighting new drugs inspired by gut incretin hormones.

Administering 1.0 mg of Semaglutide led to a 24% decrease in occurrences related to kidney disease among individuals with type 2 diabetes and persistent kidney conditions.

Codeine, a diminutive molecular compound, exerts its agonistic influence upon opioid receptors situated within the central nervous system.

Gilead Sciences and Merck unveil preliminary results from stage two trial revealing that a weekly oral blend of Islatravir and Lenacapavir successfully sustained control over viral levels up to the 24-week mark.